| abstract |
An object of the present invention is to provide a monitoring method capable of accurately confirming the effect of antienzyme drug administration, the timing of administration, and the like in the treatment of acute pancreatitis and acute circulatory failure. A method of monitoring treatment with administration of a protease inhibitory therapeutic agent detects the concentration of fibrin degradation products caused by granulocyte-derived elastase in a biological fluid sample from a patient to which the protease inhibitory therapeutic agent has been administered. [Selection diagram] Fig. 1 |